Education
About Us
Working with TipRanks
Follow Us
CellaVision AB (SE:CEVI)
:CEVI
Top Page
CellaVision AB
(OTC:CEVI)
72Outperform
CellaVision AB (CEVI) vs. S&P 500 (SPY)
Market Cap
kr4.57B
Dividend Yield1.25%
Average Volume (3M)23.96K
Price to Earnings (P/E)29.8
Beta (1Y)0.83
Revenue Growth5.60%
EPS Growth7.72%
CountrySE
Employees228
SectorHealthcare
Sector Strength38
IndustryMedical - Devices
Share Statistics
EPS (TTM)1.70
Shares Outstanding23,851,547
10 Day Avg. Volume24,817
30 Day Avg. Volume23,961
Financial Highlights & Ratios
PEG Ratio3.75
Price to Book (P/B)5.54
Price to Sales (P/S)0.00
P/FCF Ratio70.05
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
CellaVision AB Business Overview & Revenue Model
Company DescriptionCellaVision AB (CEVI) is a pioneering company in the field of medical technology, specializing in digital solutions for medical microscopy. The company focuses on developing and marketing innovative software and hardware solutions that automate and enhance the quality of blood cell analysis in laboratories around the world. CellaVision's products are primarily used in hematology, helping medical professionals accurately classify and diagnose blood disorders with greater efficiency and reliability.
How the Company Makes MoneyCellaVision makes money by selling its proprietary software and hardware solutions to clinical laboratories, hospitals, and other healthcare facilities. The company's revenue model is primarily based on the sale of its digital cell morphology analyzers and the accompanying software licenses. CellaVision also generates income through service agreements and customer support contracts, ensuring continuous operation and maintenance of its systems. Additionally, the company may engage in significant partnerships with distributors and healthcare organizations to expand its market reach and enhance its product offerings, contributing to its earnings.
CellaVision AB Financial Statement Overview
Summary
CellaVision AB exhibits strong financial health with robust revenue growth and profitability. The balance sheet is stable with low leverage, providing resilience against economic fluctuations. Cash flow generation is healthy, although there is potential to enhance free cash flow conversion. Overall, CellaVision is well-positioned in the Medical Devices industry.Income Statement
CellaVision AB has demonstrated strong growth with a consistent increase in total revenue over the years, achieving a revenue growth rate of 3.41% in the TTM. The gross profit margin is robust at 68.47% for the TTM, indicating effective cost management. The net profit margin of 20.34% reflects solid profitability. Both EBIT and EBITDA margins are strong, at 26.20% and 31.53% respectively, showcasing operational efficiency.85
Very Positive
Balance Sheet
The balance sheet of CellaVision is solid with a low debt-to-equity ratio of 0.03, indicating minimal leverage. The equity ratio stands at a healthy 80.31%, showcasing financial stability. Return on equity is impressive at 18.14%, reflecting efficient use of shareholder funds. However, the low liability level might suggest underutilized leverage potential.78
Positive
Cash Flow
CellaVision's cash flow position is stable with a positive free cash flow growth rate. The operating cash flow to net income ratio is 1.24, indicating good cash generation relative to earnings. However, the free cash flow to net income ratio at 0.44 suggests room for improvement in converting earnings into free cash flow.72
Positive
| Breakdown | |||||
| TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 747.94M | 723.22M | 677.29M | 639.34M | 565.55M | 471.44M | Gross Profit |
| 512.22M | 487.07M | 463.04M | 438.32M | 392.30M | 313.04M | EBIT |
| 195.98M | 177.68M | 167.05M | 158.27M | 162.73M | 110.27M | EBITDA |
| 236.47M | 219.75M | 207.25M | 190.87M | 193.60M | 124.60M | Net Income Common Stockholders |
| 152.12M | 140.72M | 130.31M | 118.33M | 125.34M | 89.48M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 182.32M | 149.43M | 121.64M | 108.05M | 130.29M | 102.26M | Total Assets |
| 1.04B | 1.01B | 928.71M | 891.75M | 825.21M | 668.02M | Total Debt |
| 22.96M | 26.85M | 64.70M | 102.50M | 136.65M | 132.78M | Net Debt |
| -159.36M | -122.58M | -56.94M | -5.56M | 6.37M | 30.52M | Total Liabilities |
| 205.34M | 196.16M | 212.32M | 250.12M | 281.93M | 238.41M | Stockholders Equity |
| 838.53M | 815.73M | 716.39M | 641.63M | 543.28M | 429.62M |
| Cash Flow | Free Cash Flow | ||||
| 66.26M | 120.69M | 109.96M | 67.85M | 75.41M | 37.47M | Operating Cash Flow |
| 188.51M | 198.44M | 196.44M | 137.28M | 159.72M | 71.12M | Investing Cash Flow |
| -80.37M | -76.01M | -85.53M | -70.01M | -84.34M | -34.96M | Financing Cash Flow |
| -88.45M | -95.09M | -97.04M | -90.41M | -48.48M | -35.22M |
CellaVision AB Technical Analysis
Positive
194.60
Price Trends
169.27
Positive
188.10
Positive
219.71
Negative
Market Momentum
9.03
Negative
63.95
Neutral
49.75
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:CEVI, the sentiment is Positive. The current price of 194.6 is above the 20-day moving average (MA) of 175.72, above the 50-day MA of 169.27, and below the 200-day MA of 219.71, indicating a neutral trend. The MACD of 9.03 indicates Negative momentum. The RSI at 63.95 is Neutral, neither overbought nor oversold. The STOCH value of 49.75 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:CEVI.
CellaVision AB Peers Comparison
Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | kr1.08B | 33.25 | 10.11% | ― | 2.53% | -44.90% | |
72 Outperform | kr4.57B | 29.79 | 18.49% | 1.25% | 5.60% | 7.72% | |
66 Neutral | kr6.51B | 69.90 | 1.21% | 0.59% | 7.30% | 29.44% | |
52 Neutral | $5.15B | 3.05 | -44.13% | 2.84% | 16.42% | -0.48% | |
47 Neutral | kr1.15B | ― | -42.24% | ― | ― | -19.44% | |
45 Neutral | €1.85B | ― | -40.15% | ― | ― | 63.85% |
* Healthcare Sector Average
Performance Comparison
SE:CEVI
CellaVision AB
190.00
-42.05
-18.12%
SE:CRAD.B
C-Rad AB Class B
31.90
-7.95
-19.95%
SE:SECARE
Swedencare AB
40.35
-14.30
-26.16%
SE:VICO
Vicore Pharma Holding AB
8.55
-10.62
-55.39%
SE:XSPRAY
Xspray Pharma AB
31.00
-25.82
-45.44%
CellaVision AB Earnings Call Summary
Earnings Call Date:Apr 29, 2025
(Q3-2024)
| % Change Since: 22.41%|
Next Earnings Date:Jul 18, 2025
Earnings Call Sentiment Neutral
The call reflected a mix of strong growth in EMEA and positive strategic developments, offset by challenges in the Americas and APAC regions, and increased expenses. Despite some regional and financial fluctuations, the company's strategic initiatives and growth in core areas provide a balanced outlook.Q3-2024 Updates
Positive Updates
Strong Sales in EMEA
EMEA experienced very strong growth across multiple markets and product groups, achieving an all-time high in sales even after accounting for early orders.
Organic Growth and Improved Gross Margin
The company reported an organic growth of 9% and an increase in gross margin from 66% to 68%.
Strategic Partnership with Sysmex
Continued development of strategic partnership with Sysmex, including joint training and marketing activities.
Progress in Clinical Validation
Progress according to plan on clinical validations for the bone marrow product, with a launch expected in 2025.
Reagent Growth
Reagents showed an 11% growth, with significant performance in EMEA.
Negative Updates
Decline in Americas
Sales declined in the Americas due to political uncertainties affecting hospital order placements.
APAC Revenue Fluctuations
APAC experienced fluctuations, with no shipments to China this quarter, resulting in a revenue drop from SEK 22 million to SEK 12 million.
Increased R&D Expenses
R&D expenses rose, driven by the execution of clinical trials and the maturation of multiple programs.
Cash Flow Impacted by Working Capital
Cash flow appeared weaker than the comparable quarter, affected by working capital changes, particularly in accounts receivable and inventory.
Company Guidance
During the Q3 2024 earnings call for CEVI.ST, the executives provided guidance highlighting an organic growth of 9%, achieving a revenue of SEK 179 million compared to SEK 168 million from the previous year. The EBITDA margin was reported at 27%, equivalent to SEK 49 million. The company experienced strong sales in the EMEA region with a 50% sequential growth in instrument sales, while sales declined by 20% in the Americas due to political uncertainties affecting hospital order placements. APAC showed fluctuations, with a notable absence of shipments to China this quarter. Gross margins improved from 66% to 68%, largely driven by the implementation of price increases. Additionally, the company is progressing on strategic partnerships and clinical validation, aiming to launch a bone marrow product with a CE Mark in Europe by 2025. R&D expenses constituted 22% of sales, reflecting investments in maturing development programs, including advancements in FPM technology. The cash flow for the quarter stood at SEK 16 million, with inventory levels gradually decreasing towards normal levels.CellaVision AB Corporate Events
CellaVision Announces CFO Departure Amidst Continued Growth
May 14, 2025
CellaVision AB announced the departure of its CFO, Magnus Blixt, who will leave the company on July 18, 2025, after twelve years of service. His contributions have been significant in the company’s growth and success, and the search for his replacement will begin immediately. This change in management comes as CellaVision continues to expand its product portfolio and market presence, maintaining its focus on delivering profitable growth.
CellaVision AB AGM Approves Financials and Strategic Resolutions
May 6, 2025
At its Annual General Meeting, CellaVision AB resolved to adopt the financial statements for 2024, approve a dividend of SEK 2.50 per share, and re-elect key board members, including Mikael Worning as Chairman. The AGM also authorized the board to repurchase and transfer shares, aiming to optimize capital structure and enhance shareholder value, while facilitating working capital procurement and ownership base expansion.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.